AACR Conference on Pediatric Cancer: Investigating the cyclin A/B RxL inhibitor CID-078 in pediatric cancers with RB1 loss and high E2F1

Circle Pharma Inc. published this content on October 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 02, 2026 at 14:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]